Pablo Umaña

Founder en Roche Glycart AG .

Health Technology

Perfil

Pablo Umaña is the founder of Roche Glycart AG, which was founded in 2000.
He held the title of Research Director at the time of founding.
Additionally, he worked as Head-Cancer Immunotherapy Discovery at Roche Holding AG in a former position.

Cargos activos de Pablo Umaña

Empresas	Cargo	Inicio
Roche Glycart AG Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.	Founder	01/09/2000

Todos los cargos activos de Pablo Umaña

Antiguos cargos conocidos de Pablo Umaña.

Empresas	Cargo	Fin
ROCHE HOLDING AG	Corporate Officer/Principal	-

Ver el detalle de la experiencia de Pablo Umaña.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Pablo Umaña.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
ROCHE HOLDING AG	Health Technology

Empresas privadas	1
Roche Glycart AG Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.	Health Technology